Jeffrey Berger, Md: Deciding Between Glp1 Agonists Or Sglt2 Inhibitors

Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

Peter Toth, MD: GLP-1 Agonists and SGLT-2 Inhibitors for Diabetes

Using GLP-1 Agonists & SGLT-2 Inhibitors Together from the Cardiologist's Perspective (SGLT2 & GLP1)

Understanding How SGLT2 Inhibitors and GLP-1 Agonists Work - Medpage Today

Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?

Jeffrey Berger, MD: Importance of Real-World Data

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Robert Gabbay, MD, PhD: The Debate About SGLT-2 Inhibitors and GLP-1 Receptor Agonists

Jeffrey Berger, MD: Implications of New Aspirin Data in 2019

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

Endocrine Society

Episode 93: Dr. Jeffrey Berger, Cardiologist

Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes

Jeffrey Berger, MD: Impact of TAVR on Antithrombotic Strategy

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'

At the Limits - Leading Medical Education

Dr Darren McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

SGLT2 Inhibitors for Diabetics

SGLT2 Inhibitors and GLP1 Receptor Agonists Reduce All-Cause Mortality Among Other Patient Benefits

Family & Community Medicine Grand Rounds